OBJECTIVES: Antidepressants, among the most commonly prescribed medications, trigger symptoms of REM sleep behavior disorder (RBD) in up to 6% of users. Idiopathic RBD is a very strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes. It is therefore critically important to understand whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration. DESIGN: Prospective cohort study. SETTING: Tertiary sleep disorders center. PARTICIPANTS: 100 patients with idiopathic RBD, all with diagnosis confirmed on polysomnography, stratified to baseline antidepressant use, with 45 matched controls. MEASUREMENTS/ RESULTS: Of 100 patients, 27 were taking antidepressants. Compared to matched controls, RBD patients taking antidepressants demonstrated significant abnormalities of 12/14 neurodegenerative markers tested, including olfaction (P = 0.007), color vision (P = 0.004), Unified Parkinson Disease Rating Scale II and III (P < 0.001 and 0.007), timed up-and-go (P = 0.003), alternate tap test (P = 0.002), Purdue Pegboard (P = 0.007), systolic blood pressure drop (P = 0.029), erectile dysfunction (P = 0.002), constipation (P = 0.003), depression indices (P < 0.001), and prevalence of mild cognitive impairment (13% vs. 60%, P < 0.001). All these abnormalities were indistinguishable in severity from RBD patients not taking antidepressants. However, on prospective follow-up, RBD patients taking antidepressants had a lower risk of developing neurodegenerative disease than those without antidepressant use (5-year risk = 22% vs. 59%, RR = 0.22, 95%CI = 0.06, 0.74). CONCLUSIONS: Although patients with antidepressant-associated RBD have a lower risk of neurodegeneration than patients with "purely-idiopathic" RBD, markers of prodromal neurodegeneration are still clearly present. Development of RBD with antidepressants can be an early signal of an underlying neurodegenerative disease.
OBJECTIVES: Antidepressants, among the most commonly prescribed medications, trigger symptoms of REM sleep behavior disorder (RBD) in up to 6% of users. Idiopathic RBD is a very strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes. It is therefore critically important to understand whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration. DESIGN: Prospective cohort study. SETTING: Tertiary sleep disorders center. PARTICIPANTS: 100 patients with idiopathic RBD, all with diagnosis confirmed on polysomnography, stratified to baseline antidepressant use, with 45 matched controls. MEASUREMENTS/ RESULTS: Of 100 patients, 27 were taking antidepressants. Compared to matched controls, RBD patients taking antidepressants demonstrated significant abnormalities of 12/14 neurodegenerative markers tested, including olfaction (P = 0.007), color vision (P = 0.004), Unified Parkinson Disease Rating Scale II and III (P < 0.001 and 0.007), timed up-and-go (P = 0.003), alternate tap test (P = 0.002), Purdue Pegboard (P = 0.007), systolic blood pressure drop (P = 0.029), erectile dysfunction (P = 0.002), constipation (P = 0.003), depression indices (P < 0.001), and prevalence of mild cognitive impairment (13% vs. 60%, P < 0.001). All these abnormalities were indistinguishable in severity from RBD patients not taking antidepressants. However, on prospective follow-up, RBD patients taking antidepressants had a lower risk of developing neurodegenerative disease than those without antidepressant use (5-year risk = 22% vs. 59%, RR = 0.22, 95%CI = 0.06, 0.74). CONCLUSIONS: Although patients with antidepressant-associated RBD have a lower risk of neurodegeneration than patients with "purely-idiopathic" RBD, markers of prodromal neurodegeneration are still clearly present. Development of RBD with antidepressants can be an early signal of an underlying neurodegenerative disease.
Entities:
Keywords:
Parkinson disease; REM sleep behavior disorder; antidepressants
Authors: R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross Journal: Neurology Date: 2001-08-14 Impact factor: 9.910
Authors: Marc G Weisskopf; Honglei Chen; Michael A Schwarzschild; Ichiro Kawachi; Alberto Ascherio Journal: Mov Disord Date: 2003-06 Impact factor: 10.338
Authors: Stuart J McCarter; David J Sandness; Allison R McCarter; John C Feemster; Luke N Teigen; Paul C Timm; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Neurology Date: 2019-08-16 Impact factor: 9.910
Authors: Ronald B Postuma; Alex Iranzo; Birgit Hogl; Isabelle Arnulf; Luigi Ferini-Strambi; Raffaele Manni; Tomoyuki Miyamoto; Wolfgang Oertel; Yves Dauvilliers; Yo-El Ju; Monica Puligheddu; Karel Sonka; Amelie Pelletier; Juan Santamaria; Birgit Frauscher; Smaranda Leu-Semenescu; Marco Zucconi; Michele Terzaghi; Masayuki Miyamoto; Marcus M Unger; Bertrand Carlander; Maria-Livia Fantini; Jacques Y Montplaisir Journal: Ann Neurol Date: 2015-03-13 Impact factor: 10.422
Authors: Birgit Frauscher; Poul Jennum; Yo-El S Ju; Ronald B Postuma; Isabelle Arnulf; Valerie Cochen De Cock; Yves Dauvilliers; Maria L Fantini; Luigi Ferini-Strambi; David Gabelia; Alex Iranzo; Smaranda Leu-Semenescu; Thomas Mitterling; Masayuki Miyamoto; Tomoyuki Miyamoto; Jacques Y Montplaisir; Wolfgang Oertel; Amélie Pelletier; Paolo Prunetti; Monica Puligheddu; Joan Santamaria; Karel Sonka; Marcus Unger; Christina Wolfson; Marco Zucconi; Michele Terzaghi; Birgit Högl; Geert Mayer; Raffaele Manni Journal: Neurology Date: 2014-02-19 Impact factor: 9.910